France Cancer Diagnostics Market Size & Outlook, 2023-2030
France cancer diagnostics market, 2018-2030 (US$M)
Related Markets
France cancer diagnostics market highlights
- The France cancer diagnostics market generated a revenue of USD 3,470.6 million in 2023 and is expected to reach USD 5,349.4 million by 2030.
- The France market is expected to grow at a CAGR of 6.4% from 2024 to 2030.
- In terms of segment, consumables was the largest revenue generating product in 2023.
- Consumables is the most lucrative product segment registering the fastest growth during the forecast period.
Cancer diagnostics market data book summary
| Market revenue in 2023 | USD 3,470.6 million |
| Market revenue in 2030 | USD 5,349.4 million |
| Growth rate | 6.4% (CAGR from 2023 to 2030) |
| Largest segment | Consumables |
| Fastest growing segment | Consumables |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Services, Instruments, Consumables |
| Key market players worldwide | Abbott Laboratories, Roche Holding AG, GE HealthCare Technologies Inc Common Stock, Qiagen NV, Becton Dickinson & Co, Koninklijke Philips NV, Siemens Healthineers AG ADR, Hologic Inc, Thermo Fisher Scientific Inc, Illumina Inc |
Other key industry trends
- In terms of revenue, France accounted for 3.2% of the global cancer diagnostics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany cancer diagnostics market is projected to lead the regional market in terms of revenue in 2030.
- Germany is the fastest growing regional market in Europe and is projected to reach USD 9,637.9 million by 2030.
Consumables was the largest segment with a revenue share of 60.01% in 2023. Horizon Databook has segmented the France cancer diagnostics market based on services, instruments, consumables covering the revenue growth of each sub-segment from 2018 to 2030.
France’s market is projected to grow at a lucrative rate during the forecast period, owing to high cancer prevalence and the increasing burden of chronic diseases on the healthcare industry. In October 2022, the My Personal Breast Cancer Screening (MyPeBS) clinical trial was conducted in Belgium to evaluate a breast cancer screening plan based on individual risk.
Similarly, in June 2021, Bayer and ZERO – The End of Prostate Cancer announced the launch of a national prostate cancer education program to increase awareness about cancer screening & treatment. Such factors are expected to boost the country’s market in the coming years.
Furthermore, in March 2024, Lunit announced a strategic initiative in Europe, securing two significant commercial deals and signaling its expansion in the region. The first deal involved a supply contract with France-based TeleDiag, the country’s largest teleradiology group.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Diagnostics Market Scope
Cancer Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
France cancer diagnostics market size, by product, 2018-2030 (US$M)
France Cancer Diagnostics Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
